{
    "organizations": [],
    "uuid": "4ab02e5097142dfbdef8f2afab91bad0fc2c7d15",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zhejiang-huahai-pharmaceutical-pas/brief-zhejiang-huahai-pharmaceutical-passes-fda-approval-idUSL3N1RV44E",
    "ord_in_thread": 0,
    "title": "BRIEF-Zhejiang Huahai Pharmaceutical passes FDA approval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd\n* Says it received approval for its primary hypertension treatment drug from U.S Food and Drug Administration\nSource text in Chinese: goo.gl/r5pnA6\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-04-18T17:55:00.000+03:00",
    "crawled": "2018-04-19T14:41:07.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "zhejiang",
        "huahai",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "received",
        "approval",
        "primary",
        "hypertension",
        "treatment",
        "drug",
        "food",
        "drug",
        "administration",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}